Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.

NCT01627314 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT01627314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01627314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Lead sponsor
Fate Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2012
Completion date
May 31, 2017
Enrollment
62 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies